Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated

Can Antisynthetase Syndrome Be Treated With Just Prednisone?

At a Glance

Prednisone is often used first to quickly calm inflammation in antisynthetase syndrome, but it is usually not enough as the only long-term treatment. Many patients need another medicine that calms the immune system to reduce flares, help protect lung function, and lower prednisone safely.

Prednisone (and other corticosteroids) is generally not recommended as the only long-term treatment for antisynthetase syndrome. While high-dose steroids are often an important first step to quickly calm active inflammation, they are frequently not sufficient or safe as the only long-term therapy [1]. For many patients, doctors recommend adding medications known as steroid-sparing immunosuppressants [1][2]. The exact treatment plan, however, must be individualized based on which organs are affected, disease severity, your overall health, and potential medication risks.

The Initial Role of Steroids

High-dose glucocorticoids, such as prednisone, are a mainstay for induction therapy—meaning the initial treatment used to quickly get active disease under control [1]. They work rapidly to reduce inflammation in the lungs and muscles [3]. However, antisynthetase syndrome tends to be a chronic condition that requires ongoing, carefully managed suppression of the immune system [4].

Why Steroids Alone Often Fall Short

While treatment plans vary, attempting to manage the disease long-term with only steroids has been associated with several challenges in observational studies:

  • Risk of Relapse: In reviews of patient cases, roughly half of patients treated with corticosteroid monotherapy (steroids alone) experienced a relapse or flare-up of their symptoms [1].
  • Flares During Tapering: Flares frequently happen when doctors try to lower the prednisone dose. One observational study found that nearly 60% of patients experienced a flare, often as their dose was lowered to around 11 mg per day. However, this is not a universal threshold, and tapering should always be individualized to your specific situation [5].
  • Worse Lung Outcomes: Relying only on prednisolone has been linked in some studies to a significantly higher risk of progression of interstitial lung disease (ILD)—inflammation and scarring of the lungs—compared to using combination therapy [2].

The Danger of Irreversible Damage

Without a comprehensive treatment plan, active antisynthetase syndrome can cause permanent harm:

  • Lung Damage: Interstitial lung disease can progress to permanent fibrosis (scarring) even after an initial positive response to steroids [6]. Adding an immunosuppressant early may help stabilize lung function in many patients [7][2].
  • Muscle Damage: The disease can cause severe muscle weakness, muscle atrophy (wasting away), and dysphagia (difficulty swallowing) [8].

The Risks of Long-Term Steroid Use

The goal of treatment is to control the disease while lowering the steroid dose to the lowest effective amount, or stopping it entirely if safe [4]. Staying on high doses of prednisone for a long time causes serious health problems. Prolonged exposure increases the risk of serious infections that require hospitalization and elevates cardiovascular (heart and blood vessel) risks [9][10]. Other critical long-term risks include bone loss and fractures, high blood sugar, high blood pressure, cataracts or glaucoma, mood changes, and adrenal suppression.

Safety Warning: Never Stop Steroids Abruptly
Do not change or stop your prednisone dose on your own. Sudden discontinuation after prolonged use can cause a dangerous condition called adrenal insufficiency, as well as a severe disease flare. Always follow your prescriber’s taper schedule. Seek urgent care for rapidly worsening breathlessness, low oxygen readings, chest pain, inability to swallow safely, or signs of serious infection.

Common Steroid-Sparing Approaches

To help protect your organs and reduce the need for steroids, specialists often add a steroid-sparing medicine. These drugs help control the overactive immune system, allowing your doctor to safely taper prednisone. These are common options, though your specific treatment will depend on your unique situation:

  • Mycophenolate mofetil and azathioprine: Frequently used early on, especially when lung disease is present, to help stabilize lung function and allow for steroid reduction [11][12]. These require regular blood count and liver monitoring. Mycophenolate has strict pregnancy and contraception considerations.
  • Calcineurin inhibitors (such as tacrolimus): These immune-suppressing drugs are often used alongside steroids to improve lung outcomes and reduce myositis (muscle inflammation) flares [13][5]. They require careful monitoring of kidney function, blood pressure, and drug levels in the blood.
  • Rituximab: A biologic therapy (a drug derived from living organisms that targets specific parts of the immune system) often used for severe or progressive disease, or when patients do not respond to other therapies. Some studies show it may help stabilize lung function and reduce the need for steroids [14][15]. It requires infection screening (like hepatitis B) and monitoring of your immune system’s antibody levels.

Common questions in this guide

Is prednisone alone enough to control antisynthetase syndrome?
Prednisone is often used at high doses first to quickly reduce active inflammation, but it is generally not recommended as the only long-term treatment. Many patients need a steroid-sparing immune-suppressing medicine to help control the disease and reduce the prednisone dose.
Why do doctors add a steroid-sparing medicine?
These medicines can help prevent flares, support lung function, and make it possible to lower prednisone more safely. The choice depends on which organs are affected, how severe the disease is, your overall health, and medication risks.
Can antisynthetase syndrome flare when prednisone is tapered?
Yes, flares can occur as prednisone is lowered, especially if the disease is not adequately controlled with another treatment. Tapering must be individualized, and you should not change the dose yourself.
What are the risks of taking prednisone long term?
Long-term or high-dose prednisone can increase the risk of serious infections, bone loss and fractures, high blood sugar, high blood pressure, eye problems, mood changes, and adrenal suppression. Your clinician can help reduce these risks by using the lowest effective dose and monitoring you.
Which medicines may be used with prednisone for antisynthetase syndrome?
Common steroid-sparing options include mycophenolate mofetil, azathioprine, tacrolimus, and rituximab. These medicines require different monitoring, such as blood counts, liver or kidney tests, blood pressure checks, infection screening, or drug-level monitoring, so the choice should be made with your specialist.

Get notified when new evidence is published on Antisynthetase syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    [Anti-synthetase syndrome treatment].

    Martellosio JP, Martin M, Broca F, et al.

    La Revue de medecine interne 2026; doi:10.1016/j.revmed.2026.07.008.

    PMID: 42562676
  2. 2

    Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.

    Hozumi H, Fujisawa T, Nakashima R, et al.

    The Journal of rheumatology 2019; (46(5)):509-517 doi:10.3899/jrheum.180778.

    PMID: 30647164
  3. 3

    Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease.

    Zhao N, Jiang W, Wu H, et al.

    Frontiers in immunology 2022; (13()):872615 doi:10.3389/fimmu.2022.872615.

    PMID: 36032132
  4. 4

    [Treatment Strategies for Anti-Synthetase Syndrome].

    Nakashima R

    Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(5)):655-659 doi:10.11477/mf.1416202656.

    PMID: 38741509
  5. 5

    Clinical features and risk factors of flare in anti-synthetase syndrome.

    Hasegawa A, Kurasawa K, Koike R, et al.

    Clinical rheumatology 2025; (44(6)):2431-2438 doi:10.1007/s10067-025-07398-9.

    PMID: 40205268
  6. 6

    Idiopathic inflammatory myopathies related lung disease in adults.

    Sehgal S, Patel A, Chatterjee S, et al.

    The Lancet. Respiratory medicine 2025; (13(3)):272-288 doi:10.1016/S2213-2600(24)00267-4.

    PMID: 39622261
  7. 7

    Antisynthetase Syndrome-Associated Interstitial Lung Disease: Monitoring of Immunosuppressive Treatment Effects by Chest Computed Tomography.

    Korsten P, Rademacher JG, Riedel L, et al.

    Frontiers in medicine 2020; (7()):609595 doi:10.3389/fmed.2020.609595.

    PMID: 33569387
  8. 8

    Skeletal Muscle Involvement in Antisynthetase Syndrome.

    Noguchi E, Uruha A, Suzuki S, et al.

    JAMA neurology 2017; (74(8)):992-999 doi:10.1001/jamaneurol.2017.0934.

    PMID: 28586844
  9. 9

    Optimal glucocorticoid tapering in anti-synthetase syndrome-associated interstitial lung disease: A multicentre MYKO cohort study.

    Miyake H, Kotani T, Suzuka T, et al.

    Modern rheumatology 2026; doi:10.1093/mr/roag044.

    PMID: 42143579
  10. 10

    Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study.

    Oreska S, Storkanova H, Kudlicka J, et al.

    Frontiers in medicine 2022; (9()):861419 doi:10.3389/fmed.2022.861419.

    PMID: 35602501
  11. 11

    [Clinical and radiological features of adult patients with different antisynthetase syndrome based on serum anti-aminoacyl-tRNA synthetase antibody type].

    Li S, Huang H, Song XY, et al.

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2017; (40(12)):919-924 doi:10.3760/cma.j.issn.1001-0939.2017.12.011.

    PMID: 29224302
  12. 12

    Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

    Huapaya JA, Silhan L, Pinal-Fernandez I, et al.

    Chest 2019; (156(5)):896-906 doi:10.1016/j.chest.2019.05.023.

    PMID: 31238042
  13. 13

    Management of Myositis-Associated Interstitial Lung Disease.

    Fujisawa T

    Medicina (Kaunas, Lithuania) 2021; (57(4)) doi:10.3390/medicina57040347.

    PMID: 33916864
  14. 14

    Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study.

    Langlois V, Gillibert A, Uzunhan Y, et al.

    The Journal of rheumatology 2020; (47(11)):1678-1686 doi:10.3899/jrheum.190505.

    PMID: 32173654
  15. 15

    Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.

    de Souza FHC, Miossi R, de Moraes JCB, et al.

    Advances in rheumatology (London, England) 2018; (58(1)):31 doi:10.1186/s42358-018-0030-z.

    PMID: 30657080

This page is for informational purposes only and does not constitute medical advice about antisynthetase syndrome. Do not change or stop prednisone without following your prescriber's taper plan.